CRVS vs NKTR
CRVS: A clinical-stage biopharmaceutical company developing targeted ITK inhibitors to modulate immune function for the treatment of cancer and inflammatory diseases. NKTR: A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | CRVS | NKTR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.99 | $69.32 | |
| Market cap as of 2026-07-23 | $1.2B | $2.4B | |
| Net margin as of 2026-07-23 | n/a | -280.8% | |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | n/a | -242.0% | |
| ROE as of 2026-07-23 | -38.9% | -45.8% | CRVS higher |
| ROA as of 2026-07-23 | -35.8% | -40.3% | CRVS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.10 | CRVS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -36.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -15.7% | |
| Beta as of 2026-07-23 | 0.93 | 1.13 | |
| 1-year return as of 2026-07-22 close | +225.2% | +183.2% | CRVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.